A novel transcriptional mechanism of cell type-specific regulation of vascular gene expression by glucose

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 3, 2011, Pages 634-642

  Raman, Priya ^a,b   Harry, Christy ^a   Weber, Malory ^a   Krukovets, Irene ^a   Stenina, Olga I ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Northeastern Ohio Medical University   (United States)

Author keywords

aryl hydrocarbon receptor (AhR); glucose; IRF 1; smooth muscle cell; thrombospondin 1

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; DNA; EARLY GROWTH RESPONSE FACTOR 1; GLUCOSE; INTERFERON REGULATORY FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; STAT1 PROTEIN; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR; UPSTREAM STIMULATORY FACTOR 1;

ARTICLE; CELL ACTIVATION; CELL TYPE; CONTROLLED STUDY; DNA BINDING; ENDOTHELIUM CELL; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; UPREGULATION;

BINDING SITES; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; DIABETIC ANGIOPATHIES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENDOTHELIAL CELLS; GLUCOSE; HUMANS; MUSCLE, SMOOTH, VASCULAR; MUTATION; MYOCYTES, SMOOTH MUSCLE; PROMOTER REGIONS, GENETIC; RECEPTORS, ARYL HYDROCARBON; THROMBOSPONDIN 1; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION;

EID: 79952191537     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.219675     Document Type: Article

References (36)

1. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S; Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294-2303. (Pubitemid 36638103)
2. Barzilay JI, Spiekerman CF, Kuller LH, Burke GL, Bittner V, Gottdiener JS, Brancati FL, Orchard TJ, O'Leary DH, Savage PJ; Cardiovascular Health Study. Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: the Cardiovascular Health Study. Diabetes Care. 2001;24:1233-1239. (Pubitemid 33716404)
3. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
4. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997;314: 1512-1515. (Pubitemid 27216066)
5. Stenina OI. Regulation of vascular genes by glucose. Curr Pharm Des. 2005;11:2367-2381. (Pubitemid 40872702)
6. Knoll KE, Pietrusz JL, Liang M. Tissue-specific transcriptome responses in rats with early streptozotocin-induced diabetes. Physiol Genomics. 2005;21:222-229. (Pubitemid 40898482)
7. Majack RA, Goodman LV, Dixit VM. Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation. J Cell Biol. 1988;106:415-422. (Pubitemid 18052189)
8. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med. 2002;6:1-12. (Pubitemid 44133979)
9. Stenina OI, Krukovets I, Wang K, Zhou Z, Forudi F, Penn MS, Topol EJ, Plow EF. Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation. 2003;107:3209-3215. (Pubitemid 36793093)
10. Dabir P, Marinic TE, Krukovets I, Stenina OI. Aryl hydrocarbon receptor is activated by glucose and regulates the thrombospondin-1 gene promoter in endothelial cells. Circ Res. 2008;102:1558-1565.
11. Lee SH, Kim JW, Lee HW, Cho YS, Oh SH, Kim YJ, Jung CH, Zhang W, Lee JH. Interferon regulatory factor-1 (IRF-1) is a mediator for interferon-gamma induced attenuation of telomerase activity and human telomerase reverse transcriptase (hTERT) expression. Oncogene. 2003; 22:381-391. (Pubitemid 36194334)
12. Kano S, Sato K, Morishita Y, Vollstedt S, Kim S, Bishop K, Honda K, Kubo M, Taniguchi T. The contribution of transcription factor IRF1 to the interferon-gamma-interleukin 12 signaling axis and TH1 versus TH-17 differentiation of CD4- T cells. Nat Immunol. 2008;9:34-41. (Pubitemid 350286201)
13. Kamijo R, Harada H, Matsuyama T, Bosland M, Gerecitano J, Shapiro D, Le J, Koh SI, Kimura T, Green SJ, Mak TW, Taniguchi T, Vilcek J. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science. 1994;263:1612-1615. (Pubitemid 24128365)
14. Bertazzi PA, Zocchetti C, Pesatori AC, Guercilena S, Sanarico M, Radice L. Mortality in an area contaminated by TCDD following an industrial incident. Med Lav. 1989;80:316-329. (Pubitemid 19277005)
15. Muto H, Takizawa Y. Dioxins in cigarette smoke. Arch Environ Health. 1989;44:171-174. (Pubitemid 19201938)
16. Lofroth G, Rannug A. Ah receptor ligands in tobacco smoke. Toxicol Lett. 1988;42:131-136.
17. Vena J, Boffetta P, Becher H, Benn T, Bueno-de-Mesquita HB, Coggon D, Colin D, Flesch-Janys D, Green L, Kauppinen T, Littorin M, Lynge E, Mathews JD, Neuberger M, Pearce N, Pesatori AC, Saracci R, Steenland K, Kogevinas M. Exposure to dioxin and nonneoplastic mortality in the expanded IARC international cohort study of phenoxy herbicide and chlorophenol production workers and sprayers. Environ Health Perspect. 1998;106(Suppl 2):645-653. (Pubitemid 28256772)
18. Fritsche E, Schäfer C, Calles C, Bernsmann T, Bernshausen T, Wurm M, Hübenthal U, Cline JE, Hajimiragha H, Schroeder P, Klotz LO, Rannug A, Fürst P, Hanenberg H, Abel J, Krutmann J. Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc Natl Acad Sci U S A. 2007;104:8851-8856. (Pubitemid 47175400)
19. McMillan BJ, Bradfield CA. The aryl hydrocarbon receptor is activated by modified low-density lipoprotein. Proc Natl Acad Sci U S A. 2007; 104:1412-1417. (Pubitemid 46184018)
20. Wessely R, Hengst L, Jaschke B, Wegener F, Richter T, Lupetti R, Paschalidis M, Schömig A, Brandl R, Neumann FJ. A central role of interferon regulatory factor-1 for the limitation of neointimal hyperplasia. Hum Mol Genet. 2003;12:177-187. (Pubitemid 36124453)
21. Korashy HM, El-Kadi AO. The role of aryl hydrocarbon receptor in the pathogenesis of cardiovascular diseases. Drug Metab Rev. 2006;38: 411-450.
22. Remillard RB, Bunce NJ. Linking dioxins to diabetes: epidemiology and biologic plausibility. Environ Health Perspect. 2002;110:853-858.
23. Thackaberry EA, Bedrick EJ, Goens MB, Danielson L, Lund AK, Gabaldon D, Smith SM, Walker MK. Insulin regulation in AhR-null mice: embryonic cardiac enlargement, neonatal macrosomia, and altered insulin regulation and response in pregnant and aging AhR-null females. Toxicol Sci. 2003;76:407-417. (Pubitemid 38035434)
24. Vasquez A, Atallah-Yunes N, Smith FC, You X, Chase SE, Silverstone AE, Vikstrom KL. A role for the aryl hydrocarbon receptor in cardiac physiology and function as demonstrated by AhR knockout mice. Cardiovasc Toxicol. 2003;3:153-163. (Pubitemid 41490362)
25. Raman P, Krukovets I, Marinic TE, Bornstein P, Stenina OI. Glycosylation mediates up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin-1, by glucose in vascular smooth muscle cells. J Biol Chem. 2007;282:5704-5714. (Pubitemid 47093782)
26. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, Werner T. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics. 2005; 21:2933-2942. (Pubitemid 40916416)
27. Wang S, Skorczewski J, Feng X, Mei L, Murphy-Ullrich JE. Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-beta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J Biol Chem. 2004;279:34311-34322. (Pubitemid 39318055)
28. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820. (Pubitemid 34000785)
29. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-1625. (Pubitemid 40770750)
30. Wells L, Hart GW. O-GlcNAc turns twenty: functional implications for post-translational modification of nuclear and cytosolic proteins with a sugar. FEBS Lett. 2003;546:154-158. (Pubitemid 36782297)
31. Whelan SA, Hart GW. Proteomic approaches to analyze the dynamic relationships between nucleocytoplasmic protein glycosylation and phosphorylation. Circ Res. 2003;93:1047-1058. (Pubitemid 37485035)
32. Cuif MH, Porteu A, Kahn A, Vaulont S. Exploration of a liver-specific, glucose/insulin-responsive promoter in transgenic mice. J Biol Chem. 1993;268:13769-13772. (Pubitemid 23195482)
33. Vaulont S, Kahn A. Transcriptional control of metabolic regulation genes by carbohydrates. FASEB J. 1994;8:28-35. (Pubitemid 24047408)
34. Bayraktar M, Dündar S, Kirazli S, Teletar F. Platelet factor 4, beta-thromboglobulin and thrombospondin levels in type I diabetes mellitus patients. J Int Med Res. 1994;22:90-94. (Pubitemid 24119313)
35. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB. Role of high glucoseinduced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol. 2002;13: 894-902. (Pubitemid 34274085)
36. Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, Srivastava SK. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes. 2004;53: 2910-2920. (Pubitemid 39425917)